Company profile
Kyntra Bio, Inc. logo

Kyntra Bio, Inc.

Pipeline2 assets

  • FG-3246FOR46 / CD46 / Antibody-Drug Conjugate (ADC) / Oncology
    Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2OngoingUnited States
  • roxadustatFG-4592 / HIF-PH / Small Molecule / Rare Disease
    Anemia associated with lower-risk myelodysplastic syndromes (LR-MDS)Phase 3PlannedUnited States

Latest news8 items

All news

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo Similar rates of TI for patients treated with roxadustat were observed in

Presentation / Abstract • Phase 3Poster presentation Fri, Jun 12, 2026, 6:45 PM CEST

Kyntra Bio to Report First Quarter 2026 Financial Results

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall

Presentation / Abstract • Phase 1/2

Kyntra Bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Format: Corporate

Kyntra Bio, Inc. • Endpoint Arena